Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pierre Fabre Medicament
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed adenocarcinoma of the breast;
Documented metastatic disease previously untreated by chemotherapy;
HER2 negative (assessed by 0-1+ IHC or 2+ IHC with FISH-) on the primary tumor or on metastatic site;
Karnofsky Performance Status 70%.
You may not be if
Local relapse alone after conservative treatment or contra-lateral tumor;
Patients with symptoms suggesting CNS involvement or leptomeningeal metastases;
Concomitant hormonal therapy for metastatic breast cancer;
Prior chemotherapy in the metastatic setting;
Patients previously treated with a vinca-alkaloid, capecitabine, gemcitabine or taxanes;
Prior severe and unexpected reaction to fluoropyrimidine therapy (with or without documented DPD deficiency) or known hypersensitivity to 5-fluorouracil.
Clareo Health | Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer
